Suggestions
Christina Waters, PhD MBA
Experienced biotech executive and consultant
Christina Waters, PhD MBA, is the CEO of Archer Precision Medicine Advisory LLC.1 She is based in San Diego County, California, and has a background in both science and business, as indicated by her PhD and MBA credentials.1
Professional Background
Christina Waters has a strong scientific foundation, having studied at the California Institute of Technology.1 Her expertise likely lies in the field of precision medicine, given her role at Archer Precision Medicine Advisory LLC.
Leadership Role
As the CEO of Archer Precision Medicine Advisory LLC, Christina Waters is likely responsible for:
- Providing strategic direction for the company
- Overseeing operations and business development
- Leveraging her scientific and business expertise to guide precision medicine initiatives
LinkedIn Profile
Christina Waters' LinkedIn profile can be found at linkedin.com/in/christinawaters.1 This profile would likely provide more detailed information about her professional experience, educational background, and accomplishments in the field of precision medicine.
It's worth noting that while there are several professionals named Christina Waters on LinkedIn, the one associated with Archer Precision Medicine Advisory LLC is the individual described in this answer.
Highlights
Thank you #UK #Newborn Screening Team for the thoughtful and insightful comment in Nature Medicine and a short list of treatable diseases list if detected early.
https://rdcu.be/dLgVH
"Several prospective research studies of newborn genomic screening
are underway internationally, aiming to improve the early detection and treatment of a wide range of severe genetic conditions.
Concerns have been raised that these studies may be premature and
lead to implementation in the absence of robust evidence to inform
policy. We argue that large-scale research studies of genomic
newborn screening are timely and essential to generate the data necessary for rigorous evaluation. Exploring the benefits, harms and costs of genomic newborn screening for rare diseases.
Keep up the great work Emma L. Baple, Richard H. Scott, Siddharth Banka, James Buchanan, Louise Fish, Sarah Wynn, Dominic Wilkinson, Sian Ellard, Daniel G. MacArthur & Zornitza Stark
#rarediseases #rare #kids #newbornscreening #genetics #genomics #precisionmedicine #diagnosis #earlyintervention #united #together Genomics England Rady Children's Institute for Genomic Medicine EveryLife Foundation for Rare Diseases
Many rare diseases share the same underlying molecular etiology that are therapeutically targetable. Basket trial design based on molecular etiology, such as used in Oncology clinical trials, could potentially
•Increase the number of patients gaining access to clinical trials and decrease challenges of small population trials
•Cluster patients based on biology and stimulate innovation of precision-based medicines
•Accelerate use of existing drugs that are currently not accessible to patients that would benefit from their action
Please join Dave Pearce, P.J. Brooks and I (Christina Waters, PhD MBA) in discussing the shared platforms and technologies that are available along with challenges and opportunities for the future of basket trails for rare disease patients.
See you June 18th, 10am at #DIA2024 at the #SanDiego Convention Center!
International Rare Diseases Research Consortium (IRDiRC) Sanford Health National Center for Advancing Translational Sciences (NCATS) #rare #rarediseases #pediatrics #kids #genomics #genetics #diagnostics #clinicalbaskettrials #clinicalendpoints #clinicaltrials #R&D #research #discovery #united #datasharing #globalhealth #equity #access #precisionmedicine #drugdiscovery
